Argenx To Acquire FDA Priority Review Voucher - Quick Facts

argenx SE (ARGX) announced an agreement to acquire a FDA Priority Review Voucher for $102 million. The company expects to redeem the PRV for a future marketing application for efgartigimod, its neonatal Fc receptor blocker.

"We have demonstrated proof-of-concept in four autoimmune diseases with our first-in-class FcRn blocker, efgartigimod, and are planning to be active in fifteen disease targets by 2025. With a priority review voucher available, we hope to expedite the approval process for one of our current or future indications," said Tim Van Hauwermeiren, CEO of argenx.

A PRV entitles the holder to FDA priority review of a single Biologics License Application.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Societe Generale Group reported Wednesday a weak profit in its fourth quarter, despite higher net banking income. Further, the French Financial services major proposed a dividend and around 440 million euros share buyback program. The company also confirmed fiscal 2025 financial targets. City of Industry, California-based Titans Global Inc. is recalling certain JSJ branded cakes citing potential to contain undeclared eggs, a known allergen, the U.S. Food and Drug Administration said. The recall involves its 95g packages of JSJ Chocolate Cake, JSJ ZSR Cake, and JSJ DMC Leaf Cake food treats. Tech major Google, owned by Alphabet Inc., has unveiled a new chatbot tool called Bard. The experimental conversational artificial intelligence or AI service is built on a large language model, powered by the company's Language Model for Dialogue Applications or LaMDA.
Follow RTT